A year that has lived up to expectations
- Objective of a sales turnaround after the CMDS acquisition achieved. Slight growth in revenue expected in 2017 at constant exchange rates
- EBITDA at constant exchange rates in line with expectations
Villepinte, March 29, 2017 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is publishing its consolidated and audited annual results for 2016.
On March 28, 2017, the Board of Directors approved the financial statements for the period ended December 31, 2016.
